clinical trial · NCT06608927
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal AdenocarcinomaQuemliclustatPlaceboNab-paclitaxelGemcitabine
brief summary
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
started
Dec 13, 2024
primary completion
Nov 30, 2030
completion
Nov 30, 2030
last updated
Jul 2, 2026
official title
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol